Creating Life-Changing Medicines for Central Nervous System Disorders

Central nervous system (CNS) disorders affect millions of people around the world. However, developing and bringing to market an innovative therapy is a challenging endeavor due to a wide variety of science, research and market access factors. While the need has never been greater for better, more distinct treatments, successfully creating the next life-changing medicine requires a partner that can help you overcome a range of business challenges from product development to commercialization.

Make smarter decisions with specialized research on central nervous system disorders

  • Guidance to prioritize product development and portfolio investments
  • Resources to identify and assess market opportunities globally
  • Direction to achieve market access and optimal pricing
  • Support to build accurate forecasts based on current and future market conditions
  • Brand/promotional assessment tools to differentiate your product and drive brand success

Learn more about our research solutions

Schizophrenia — Bringing the Burden of Care into the Spotlight

schizophrenia white paperThe extent and impact of caring for an individual with schizophrenia are not well recognized in society, and caregivers do not have adequate support and resources. While previous studies indicated that significant costs are associated with caring for a patient with schizophrenia, large-scale studies are not available in Europe. 

Read more

National Health and Wellness Survey

NHWS 220x320

Kantar Health’s National Health and Wellness Survey (NHWS) is the largest global self-reported general population survey in the healthcare industry. NHWS provides disease-specific measures that help you size market opportunities, measure direct and indirect costs, and gain disease-specific insights to optimize the value proposition and inform brand strategies. Patient reported data is available for Alzheimer’s, epilepsy, schizophrenia and other central nervous system disorders.

Download Fact Sheet

Epi Database ®

Epi Database 220x320

Kantar Health’s Epi Database is the premier epidemiology database, covering Alzheimer’s, epilepsy, schizophrenia and other central nervous system disorders. It's the gold standard of epidemiology data providing reliable, rigorous research and documentation in the G7 and key emerging countries.

Download Fact Sheet

Autoimmune Patient Caregiver Studies

syndicated patient study 220x320

Kantar Health’s syndicated patient and caregiver studies provide a comprehensive view of the market landscape and patient experience for specific segments in the U.S. Studies on CNS disorders currently include Alzheimer’s Disease and Schizophrenia.

Download Fact Sheet